About this episode
Send a textLife sciences M&A is picking up again, but today’s deals look nothing like they did two years ago.In this episode, Darshan Kulkarni sits down with Stephanie Trunk, Partner at ArentFox Schiff, to unpack what’s really driving renewed deal activity and what buyers are still missing in diligence. From U.S. manufacturing incentives and drug pricing exposure to China risk, DOJ enforcement, compliance culture, and AI, this conversation goes beyond headlines and into deal reality.If you are buying, selling, or advising life sciences companies, this episode is a must-listen.Key Topics DiscussedWhy life sciences M&A slowed down and why it’s backThe shift from mega-deals to asset-specific acquisitionsWhy U.S. manufacturing location now affects deal valueAccelerated approvals and “Buy America” incentivesDrug pricing risks buyers can no longer ignoreASP, inflation rebates, Medicaid rebate cap removal, and 340B pressurePolitical risk in drug pricing and government scrutinyChina partnerships, data transfer rules, and biosecurity concernsDirect-to-patient models and new HIPAA exposureUsing Sunshine Act and other public data in diligenceCompliance programs, culture, and successor liabilityWhy compliance issues still rarely kill dealsThe emerging role of AI in diligence and enforcementThe IP diligence problem no one wants to solveWhy This Episode MattersLife sciences deals are no longer just about science and revenue projections. Manufacturing geography, pricing exposure, compliance culture, data security, and enforcement risk now directly shape valuation and post-close outcomes.Ignoring these issues does not make them go away. It just shifts the risk to the buyer.GuestStephanie Trunk Partner, ArentFox Schiff Life Sciences | CMS | OIG | Reimbursement | Fraud & AbuseStephanie advises pharmaceutical, biotech, and device companies on regulatory risk, government pricing, and transaction diligence.? stephanie.trunk@afslaw.com ? ArentFox Schiff Life Sciences BlogHostDarshan Kulkarni Founder, Kulkarni Law Firm Host, DarshanTalks? darshan@kulkarnilawfirm.com ? LinkedIn: Darshan KulkarniSubscribe & ConnectIf life sciences compliance, enforcement, or deals matter to your business, subscribe for more conversations like this. Questions or ideas for future episodes? Reach out anytime.Support the showwww.kulkarnilawfirm.com
